Posted by Michael Wonder on 03 Nov 2021
Allena Pharmaceuticals receives fast track designation from FDA for the development of ALLN-346 for chronic treatment of hyperuricemia in patients with gout and advanced chronic kidney disease
3 November 2021 - Novel oral therapeutic candidate ALLN-346 targets uric acid in the intestinal tract.
Allena Pharmaceuticals today announced that its orally-administered, urate-degrading enzyme, ALLN-346, has received fast track designation from the U.S. FDA.
